
Overview
Background
Associate Professor Victoria Atkinson is both a Senior Medical Oncologist and a Principal Investigator for clinical trials in the adjuvant and metastatic setting at the Princess Alexandra Hospital and Greenslopes Private Hospital (in collaboration with Gallipoli Medical Research Foundation). Additionally, she is an Associate Professor with the University of Queensland, Clinical School of Medicine. Associate Professor Atkinson’s research interests are in the field of Oncology, and she has extensive experience in targeted-therapies and immunotherapies. Her main research interests are melanoma and gastro-intestinal oncology. Associate Professor Atkinson is passionate about trying to improve outcome for all patients with advanced melanoma as well as advanced gastro-intestinal cancers.
Associate Professor Atkinson has been involved in the clinical development of the current targeted and immunotherapies in melanoma over the past decade bringing these therapies into clinical practice. She has been involved in advocating for patient access to these therapies for patients in Queensland and Australia from guidelines through to reimbursement policies. These therapies have revolutionised the lives of patients and brought about the longest median overall survival for advanced melanoma. However there still remains significant work to be done in therapy resistant disease and she continues to work with therapies towards overcoming resistance.
In the past 5 years, Associate Professor Atkinson has been an Invited Speaker at 22 national and international meetings including Medical Oncology Group of Australia ASM Immunotherapy Symposium, New Zealand Society for Medical Oncology meeting and the Society for Melanoma Research congress. A/Prof Atkinson has published 82 publications, 31 oral abstracts and 65 posters. Associate Professor Atkinson is actively involved in the research supervision of her basic and advanced trainees, and resident medical officers who demonstrate interest in a project. She has supervised trainees to complete their research projects and supported 6 Australian research poster presentations, and 10 international research poster presentations.
She is passionate and motivated to continue to change practice by bringing clinically important and relevant trials to Queensland and to mentor trainees and junior consultants to continue this tradition.
Availability
- Professor Victoria Atkinson is:
- Available for supervision
Research interests
-
Oncology
-
Melanoma
-
Gastro-intestinal oncology
-
Patient outcomes
Works
Search Professor Victoria Atkinson’s works on UQ eSpace
2022
Journal Article
Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy
Ng, Gary, Xu, Wen and Atkinson, Victoria (2022). Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy. Current Oncology Reports, 24 (10), 1273-1280. doi: 10.1007/s11912-022-01288-y
2022
Journal Article
Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomes
Shanker, Mihir D., Garimall, Sidyarth, Gatt, Nick, Foley, Heath, Crowley, Samuel, Le Cornu, Emma, Muscat, Kendall, Soon, Wei, Atkinson, Victoria, Xu, Wen, Watkins, Trevor, Huo, Michael, Foote, Matthew C. and Pinkham, Mark B. (2022). Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomes. Journal of Medical Imaging and Radiation Oncology, 66 (4), 536-545. doi: 10.1111/1754-9485.13403
2022
Journal Article
Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus
Atkinson, Victoria, Robert, Caroline, Grob, Jean J., Gogas, Helen, Dutriaux, Caroline, Demidov, Lev, Gupta, Avinash, Menzies, Alexander M., Ryll, Bettina, Miranda, Flora, Banerjee, Hiya, Lau, Mike and Del Vecchio, Michele (2022). Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus. European Journal of Cancer, 163, 79-87. doi: 10.1016/j.ejca.2021.12.015
2022
Journal Article
BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting
Scolyer, Richard A., Atkinson, Victoria, Gyorki, David E., Lambie, Duncan, O'Toole, Sandra, Saw, Robyn P.M., Amanuel, Benhur, Angel, Christopher M., Button-Sloan, Alison E., Carlino, Matteo S., Ch'ng, Sydney, Colebatch, Andrew J., Daneshvar, Dariush, Pires da Silva, Inês, Dawson, Tamara, Ferguson, Peter M., Foster-Smith, Erwin, Fox, Stephen B., Gill, Anthony J., Gupta, Ruta, Henderson, Michael A., Hong, Angela M., Howle, Julie R., Jackett, Louise A., James, Craig, Lee, C. Soon, Lochhead, Alistair, Loh, Daphne, McArthur, Grant A. ... Long, Georgina V. (2022). BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology, 54 (1), 6-19. doi: 10.1016/j.pathol.2021.11.002
2022
Journal Article
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis
Goldinger, Simone M., Buder-Bakhaya, Kristina, Lo, Serigne N., Forschner, Andrea, McKean, Meredith, Zimmer, Lisa, Khoo, Chloe, Dummer, Reinhard, Eroglu, Zeynep, Buchbinder, Elizabeth I., Ascierto, Paolo A., Gutzmer, Ralf, Rozeman, Elisa A., Hoeller, Christoph, Johnson, Douglas B., Gesierich, Anja, Kölblinger, Peter, Bennannoune, Naima, Cohen, Justine V., Kähler, Katharina C., Wilson, Melissa A., Cebon, Jonathan, Atkinson, Victoria, Smith, Jessica L., Michielin, Olivier, Long, Georgina V., Hassel, Jessica C., Weide, Benjamin, Haydu, Lauren E. ... Menzies, Alexander M. (2022). Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. European Journal of Cancer, 162, 22-33. doi: 10.1016/j.ejca.2021.11.022
2021
Journal Article
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
Eggermont, Alexander MM., Meshcheryakov, Andrey, Atkinson, Victoria, Blank, Christian U., Mandala, Mario, Long, Georgina V., Barrow, Catherine, Di Giacomo, Anna Maria, Fisher, Rosalie, Sandhu, Shahneen, Kudchadkar, Ragini, Ortiz Romero, Pablo Luis, Svane, Inge Marie, Larkin, James, Puig, Susana, Hersey, Peter, Quaglino, Pietro, Queirolo, Paola, Stroyakovskiy, Daniil, Bastholt, Lars, Mohr, Peter, Hernberg, Micaela, Chiarion-Sileni, Vanna, Strother, Matthew, Hauschild, Axel, Yamazaki, Naoya, van Akkooi, Alexander CJ., Lorigan, Paul, Krepler, Clemens ... Robert, Caroline (2021). Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. European Journal of Cancer, 158, 156-168. doi: 10.1016/j.ejca.2021.09.023
2021
Journal Article
5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation⇓positive advanced melanoma: extended follow-up of the coBRIM study
Ascierto, Paolo A., Dreno, Brigitte, Larkin, James, Ribas, Antoni, Liszkay, Gabriella, Maio, Michele, Mandala, Mario, Demidov, Lev, Stroyakovskiy, Daniil, Thomas, Luc, de la Cruz-Merino, Luis, Atkinson, Victoria, Dutriaux, Caroline, Garbe, Claus, Hsu, Jessie, Jones, Surai, Li, Haocheng, McKenna, Edward, Voulgari, Athina and McArthur, Grant A. (2021). 5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation⇓positive advanced melanoma: extended follow-up of the coBRIM study. Clinical Cancer Research, 27 (19), 5225-5235. doi: 10.1158/1078-0432.CCR-21-0809
2021
Journal Article
Standard-dose pembrolizumab plus alternate-dose ipilimumab in advanced melanoma: KEYNOTE-029 cohort 1C, a phase 2 randomized study of two dosing schedules
Long, Georgina V., Robert, Caroline, Butler, Marcus O., Couture, Felix, Carlino, Matteo S., O’Day, Steven, Atkinson, Victoria, Cebon, Jonathan S., Brown, Michael P., Dalle, Stephane, Hill, Andrew G., Gibney, Geoffrey T., McCune, Steven, Menzies, Alexander M., Niu, Cuizhen, Ibrahim, Nageatte, Moreno, Blanca Homet and Diab, Adi (2021). Standard-dose pembrolizumab plus alternate-dose ipilimumab in advanced melanoma: KEYNOTE-029 cohort 1C, a phase 2 randomized study of two dosing schedules. Clinical Cancer Research, 27 (19), 5280-5288. doi: 10.1158/1078-0432.CCR-21-0793
2021
Journal Article
Adjuvant nivolumab for stage III/IV melanoma: Evaluation of safety outcomes and association with recurrence-free survival
Mandala, Mario, Larkin, James, Ascierto, Paolo Antonio, Del Vecchio, Michele, Gogas, Helen, Cowey, C. Lance, Arance, Ana, Dalle, Stéphane, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Marquez, Ivan, Butler, Marcus O., Di Giacomo, Anna Maria, Lutzky, Jose, De La Cruz-Merino, Luis, Atkinson, Victoria, Arenberger, Petr, Hill, Andrew, Fecher, Leslie, Millward, Michael, Khushalani, Nikhil I., De Pril, Veerle, Lobo, Maurice and Weber, Jeffrey (2021). Adjuvant nivolumab for stage III/IV melanoma: Evaluation of safety outcomes and association with recurrence-free survival. Journal for ImmunoTherapy of Cancer, 9 (8) e003188, 1-9. doi: 10.1136/jitc-2021-003188
2021
Journal Article
Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti–PD-1 therapy
Hepner, Adriana, Atkinson, Victoria G., Larkin, James, Burrell, Rebecca A., Carlino, Matteo S., Johnson, Douglas B., Zimmer, Lisa, Tsai, Katy K., Klein, Oliver, Lo, Serigne N., Haydon, Andrew, Bhave, Prachi, Lyle, Megan, Pallan, Lalit, Pires da Silva, Ines, Gerard, Camille, Michielin, Olivier, Long, Georgina V. and Menzies, Alexander M. (2021). Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti–PD-1 therapy. European Journal of Cancer, 153, 213-222. doi: 10.1016/j.ejca.2021.04.021
2021
Journal Article
Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy
Dearden, Helen, Au, Lewis, Wang, Daniel Y., Zimmer, Lisa, Eroglu, Zeynep, Smith, Jessica L., Cuvietto, Marcello, Khoo, Chloe, Atkinson, Victoria, Lo, Serigne, Long, Georgina V., Sandhu, Shahneen, Ascierto, Paolo A., Carlino, Matteo S., Johnson, Douglas B., Larkin, James and Menzies, Alexander M. (2021). Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. European Journal of Cancer, 153, 168-178. doi: 10.1016/j.ejca.2021.04.045
2021
Journal Article
Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy
Smithers, B. Mark, Saw, Robyn P. M., Gyorki, David E., Martin, Richard C. W., Atkinson, Victoria, Haydon, Andrew, Roberts‐Thomson, Rachel and Thompson, John F. (2021). Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy. ANZ Journal of Surgery, 91 (S2), 3-13. doi: 10.1111/ans.17051
2021
Journal Article
The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis
Versluis, Judith M., Hendriks, Anne M., Weppler, Alison M., Brown, Lauren J., de Joode, Karlijn, Suijkerbuijk, Karijn P.M., Zimmer, Lisa, Kapiteijn, Ellen W., Allayous, Clara, Johnson, Douglas B., Hepner, Adriana, Mangana, Joanna, Bhave, Prachi, Jansen, Yanina J.L., Trojaniello, Claudia, Atkinson, Victoria, Storey, Lucy, Lorigan, Paul, Ascierto, Paolo A., Neyns, Bart, Haydon, Andrew, Menzies, Alexander M., Long, Georgina V., Lebbe, Celeste, van der Veldt, Astrid A.M., Carlino, Matteo S., Sandhu, Shahneen, van Tinteren, Harm, de Vries, Elisabeth G.E. ... Jalving, Mathilde (2021). The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. European Journal of Cancer, 151, 72-83. doi: 10.1016/j.ejca.2021.04.003
2021
Journal Article
A retrospective analysis of dabrafenib and/or dabrafenib plus trametinib combination in patients with metastatic melanoma to characterize patients with long-term benefit in the individual patient program (Describe iii)
Atkinson, Victoria G., Quaglino, Pietro, Aglietta, Massimo, Del Vecchio, Michele, Depenni, Roberta, Consoli, Francesca, Bafaloukos, Dimitrios, Ferrucci, Pier Francesco, Tulyte, Skaiste, Krajsová, Ivana, Ascierto, Paolo A., Gueli, Rossana, Arance, Ana, Gogas, Helen, Banerjee, Hiya, Saliba, Teddy, de Jong, Egbert and Neyns, Bart (2021). A retrospective analysis of dabrafenib and/or dabrafenib plus trametinib combination in patients with metastatic melanoma to characterize patients with long-term benefit in the individual patient program (Describe iii). Cancers, 13 (10) 2466, 1-13. doi: 10.3390/cancers13102466
2021
Journal Article
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Bottomley, Andrew, Coens, Corneel, Mierzynska, Justyna, Blank, Christian U., Mandalà, Mario, Long, Georgina V., Atkinson, Victoria G., Dalle, Stéphane, Haydon, Andrew M., Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S., Sandhu, Shahneen, Puig, Susana, Ascierto, Paolo A., Larkin, James, Lorigan, Paul C., Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Di Giacomo, Anna Maria, van den Eertwegh, Alfonsus J. M., Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, van Akkooi, Alexander C. J., Krepler, Clemens, Ibrahim, Nageatte ... for the EORTC Melanoma Group (2021). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. The Lancet Oncology, 22 (5), 655-664. doi: 10.1016/S1470-2045(21)00081-4
Featured
2021
Journal Article
Radiomics biomarkers correlate with CD8 expression and predict immune signatures in melanoma patients
Aoude, Lauren G., Wong, Bernadette, Bonazzi, Vanessa F, Brosda, Sandra, Walters, Shaun B., Koufariotis, Lambros T., Naeini, Marjan M., Pearson, John V, Oey, Harald, Patel, Kalpana, Bradford, Julia J., Bloxham, Conor J, Atkinson, Victoria, Law, Phillip, Strutton, Geoffrey, Bayley, Gerard, Yang, Samuel, Smithers, B. Mark, Waddell, Nicola, Miles, Kenneth and Barbour, Andrew P. (2021). Radiomics biomarkers correlate with CD8 expression and predict immune signatures in melanoma patients. Molecular Cancer Research, 19 (6) molcanres.1038.2020, 950-956. doi: 10.1158/1541-7786.mcr-20-1038
2021
Journal Article
Human CD141+ dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model
Lee, Yoke Seng, O'Brien, Liam J., Walpole, Carina M., Pearson, Frances E., Leal-Rojas, Ingrid M., Masterman, Kelly-Anne, Atkinson, Victoria, Barbour, Andrew and Radford, Kristen J. (2021). Human CD141+ dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model. Journal for ImmunoTherapy of Cancer, 9 (3) e001963, 1-12. doi: 10.1136/jitc-2020-001963
2021
Journal Article
Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia
Hong, Angela M., Waldstein, Cora, Shivalingam, Brindha, Carlino, Matteo S., Atkinson, Victoria, Kefford, Richard F., McArthur, Grant A., Menzies, Alexander M., Thompson, John F. and Long, Georgina V. (2021). Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia. European Journal of Cancer, 142, 10-17. doi: 10.1016/j.ejca.2020.10.013
2020
Journal Article
KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
Ferrucci, Pier Francesco, Di Giacomo, Anna Maria, Del Vecchio, Michele, Atkinson, Victoria, Schmidt, Henrik, Schachter, Jacob, Queirolo, Paola, Long, Georgina V., Stephens, Rosalie, Svane, Inge Marie, Lotem, Michal, Abu-Amna, Mahmoud, Gasal, Eduard, Ghori, Razi, Diede, Scott J., Croydon, Elizabeth S., Ribas, Antoni and Ascierto, Paolo Antonio (2020). KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. Journal for ImmunoTherapy of Cancer, 8 (2) e001806, 1-9. doi: 10.1136/jitc-2020-001806
2020
Journal Article
Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma
Atkinson, Victoria, Khattak, Adnan, Haydon, Andrew, Eastgate, Melissa, Roy, Amitesh, Prithviraj, Prashanth, Mueller, Christian, Brignone, Chrystelle and Triebel, Frederic (2020). Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. Journal for ImmunoTherapy of Cancer, 8 (2) e001681, 1-9. doi: 10.1136/jitc-2020-001681
Supervision
Availability
- Professor Victoria Atkinson is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Media
Enquiries
For media enquiries about Professor Victoria Atkinson's areas of expertise, story ideas and help finding experts, contact our Media team: